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OVERVIEW — This issue brief discusses the most recent findings on depres-
sion prevalence and cost; examines trends in outpatient treatment, including
the dramatic growth in antidepressant use; discusses efforts to improve treat-
ment in primary care; and explores possible public policy avenues for improv-
ing treatment access and quality.
2
NHPF Issue Brief No.786 / November 22, 2002
National Health Policy Forum
2131 K Street NW, Suite 500
Washington DC 20037
202/872-1390









NHPF is a nonpartisan education and
information exchange for federal
health policymakers.
Depression: A Decade of Progress,
More to Do
The economic and social costs of untreated depression have been docu-
mented worldwide. One in six persons have an episode of depression
during their lifetime, many during their most productive work years. A
landmark 1996 study found major depression was a leading cause of dis-
ability throughout the world.1 Data from U.S. employers show it is also a
major source of lost productivity at the workplace and accounts for bil-
lions of dollars in health care expenditures.
In the decade between 1987 and 1997, the number of Americans treated
for depression increased three-fold.2 Reduced stigma, increased recogni-
tion and diagnosis, and effective treatments are primary reasons behind
the trend. Still, research suggests that fewer than half of those with de-
pression are treated. And many who are receive suboptimal care.
Although the economic case for improving the recognition and treatment
of depression is compelling, mental health has not been a public health
priority. When it has been addressed, policymakers have struggled to
find the levers that improve access to high-quality treatment.
NATURE OF DEPRESSION
Depression is a serious and common medical condition affecting physi-
cal health, mood, and thoughts. Almost 19 million American adults expe-
rience an episode of depression each year.3 It recurs in about half of pa-
tients and can be severely disabling. Up to 35 percent of all deaths by
suicide are associated with depression.
At some point in their lives, most people experience depression’s symp-
toms, including deep sadness, grief, and sleep disturbances, due to life
events such as loss of a loved one. But clinical depression is different in
some important ways. The 1999 surgeon general’s report on mental
health notes:
Some of the symptoms of severe depression, such as anhedonia (the
inability to experience pleasure), hopelessness, and loss of mood reac-
tivity (the ability to feel a mood uplift in response to something posi-
tive) only rarely accompany “normal” sadness. Suicidal thoughts and
psychotic symptoms such as delusions or hallucinations virtually al-
ways signify a pathological state.4
Among the most common types of depression are major depression,
dysthymia, and bipolar disorder.5 Women are at higher risk for depres-
sion than men; contributing to this elevated risk, it is hypothesized, are
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a number of social, economic, and biological reasons, including hor-
monal factors related to the menstrual cycle, pregnancy, the postpartum
period, premenopause, and menopause. Depression in men may be more
difficult to recognize, frequently showing itself as irritability and anger
or being hidden by substance abuse. Untreated, an episode of depres-
sion lasts for an average of nine months. When it recurs, the length of
time between episodes decreases over time.
People with depression often have other mental and physical illnesses.
About half of people with depression also have an anxiety disorder.6 Some
form of substance abuse or dependence is common in about a third of
those with depression. And people with depression also experience chronic
conditions, such as arthritis and musculoskeletal disorders, at higher rates.
Two decades of research show a strong relationship between depression
and heart disease, the leading cause of death in the United States. People
with depression are at greater risk for developing heart disease than
healthy individuals, and people with heart disease and depression have
an increased risk of death after a heart attack.7 A recent study illustrates
depression’s serious effect on men’s health. Researchers found depres-
sion is associated with increased risk of heart disease for both men and
women. However, men with depression and heart disease have a higher
death rate than women with the two conditions.8
Although, the exact causes of depression are unknown,9 years of research
point to a combination of biological and psychosocial factors and have
yielded a growing body of knowledge on risk factors, early intervention,
and prevention.
COST OF DEPRESSION
On average, people with depression use two to four times more health
care than people without a mental illness.10 As noted above, depression
increases risk for common chronic conditions, such as heart disease. Of-
ten, people with unrecognized depression undergo diagnostic procedures
and treatments for physical symptoms, such as headaches, chronic pain,
and digestive problems, without relief.
One study at a large U.S. corporation found that total medical expendi-
tures for people with common mental disorders, including depression,
were four-and-a-half times greater than expenditures for people with-
out mental illness. When individuals had more than one mental disor-
der, expenditures increased tenfold.11
Recent studies on the cost of treatment for depression show that utiliza-
tion of mental health services accounts for only a small portion of total
health care spending for people with the illness. Analysis of health care
utilization and expenditures over a four-year period for a group of people
with depression found “treating an uncomplicated episode of depressive
illness in this primary care population averaged a little more than $2,000,
Symptoms of Depression
■ Persistent sad, anxious or
empty mood.
■ Loss of interest or pleasure in
hobbies or activities that were
once enjoyed, including sex.
■ Decreased energy, fatigue,
being “slowed down.”
■ Insomnia, particularly early
morning awakening, or over-
sleeping.




■ Feelings of hopelessness,
pessimism.
■ Feelings of guilt, worthless-
ness, helplessness.
■ Thoughts of death or suicide,
or suicide attempts.
■ Restlessness, irritability.
If five or more of these symptoms
are present every day for at least
two weeks and interfere with rou-
tine daily activities such as work,
self-care, and child care or social
life, a thorough evaluation is recom-
mended.
Source: National Institute of Mental Health.
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and treating the most common form was significantly less.”12 In contrast,
total medical costs for those individuals averaged almost $8,000 a year.
Still, depression’s greatest costs are not for health care services. Rather,
they are indirect costs associated with disability and lost productivity at
work when depression is unrecognized or poorly treated. A 1993 study,
the most recent research of its kind, found $12 billion was spent on treat-
ment of depression in 1990. However, employers spent another $24 bil-
lion associated with lost work time and productivity. The authors con-
cluded that poor recognition and treatment of depression exposes em-
ployers to avoidable disability and productivity-related costs.
Employer experiences underscore the costly impact of untreated depres-
sion and support the value of early intervention. Depression is a common
disability claim, as both a primary and a co-occurring condition. It accounts
for about half of all psychiatric disability claims and often has the longest
average length of disability and the highest probability of recidivism.13
Research on employer-sponsored health benefits found that plans with good
access to outpatient mental health services had lower psychiatric disability
claims costs than plans with more restrictive arrangements.14
TREATMENT OF DEPRESSION
Treatments and treatment effectiveness vary with the type of depression
and its severity. There is also a growing body of knowledge about how
cultural and language differences affect mental health perceptions, de-
pression diagnosis, and treatment approaches. However, most depres-
sion can be effectively treated with medication, some specific types of
psychotherapy, or a combination of both. Research on depression treat-
ment suggests that a combination of medication and psychotherapy may
be more efficacious than either treatment alone. In addition, more severe
depression may require medication, while psychotherapy alone may be
as effective as medication for milder depression.
Results of a long-running study on medication and psychotherapy treat-
ments presented at the annual meeting of the American Psychiatric As-
sociation in 2002 challenged conventional thinking about depression
treatment. The study concluded that cognitive behavioral therapy is
just as effective as medication for severe depression. However, research-
ers determined that psychotherapy worked more slowly than medica-
tion and was not as effective in chronic cases. They also noted that it
must be administered appropriately, raising some concern about avail-
ability of skilled providers. However, investigators found the effects of
cognitive therapy may be long-lasting and therefore able to protect
against relapse.
Regardless of the ongoing debate and research into determining which
treatment will be most effective for which patients, the surgeon general’s
report on mental health notes, “so much is known about the assortment
Depression accounts
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of pharmacological and psychosocial treatments for mood disorders that
the most salient problem is not with treatment, but rather getting people
into treatment.”15
Appropriate treatment typically includes three phases: acute, continua-
tion, and maintenance.16 Within that framework, individual preferences
and circumstances, including age, gender, culture, race, and other per-
sonal characteristics, can be accommodated with a range of effective treat-
ments. Medication usually requires six to eight weeks of treatment in the
acute phase. Patients are seen once or twice a week to monitor symptoms
and medication side effects, adjust medication dosage when necessary,
and provide support. The acute phase for psychotherapies typically in-
volves 6 to 20 weekly visits.
Continuation therapy provides for continual treatment over a minimum
of six months, although patients usually see their providers less often
than during the acute phase. The primary purpose of continuation therapy
is to prevent a relapse. Maintenance therapy consists of ongoing treat-
ment to prevent a recurrence of the illness and is usually recommended
for people who have had three or more episodes of depression or have
persistent depression or bipolar disorder.17
Over the last decade, use of medications in depression treatment grew
dramatically. At least eight new antidepressants have been approved
for use in the United States since 1987, beginning with fluoxetine, a
selective serotonin reuptake inhibitor (SSRI). SSRIs and other newer an-
tidepressants tend to have fewer side effects and easier dosing regi-
mens than older medications. Before the advent of SSRIs, psychiatrists
prescribed most antidepressants. Now, nonpsychiatrists prescribe most
antidepressants, writing almost 90 million prescriptions in 1998, up from
32 million in 1988.18
A significant barrier to successful treatment is poor patient compliance
during the acute phase. Medication side effects, uninformed expectations
about treatment, and inadequate oversight by providers may result in
high attrition rates, measured at up to 40 percent in clinical trials.19 Pre-
scription drug data show that fewer than half of patients refill their initial
antidepressant prescription.20 However, tracking is not sophisticated
enough to determine whether patients are switching to another medica-
tion or just stopping treatment before the drug has a chance to provide a
therapeutic effect.
TRENDS IN OUTPATIENT CARE
Before 1990, most mental health dollars were spent in the specialty men-
tal health system on inpatient care. Typically, people accessed mental health
services through indemnity plans that used benefit limits and patient cost
sharing to control service use and spending. By the late 1990s, managed
care was the norm in health service delivery. Managed behavioral health
“[T]he most salient
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had grown into a $4.5 billion industry with almost 200 million enrollees.
Managed care was successful at controlling spending growth for mental
health services while providing access to a wider scope of services than
those offered under the traditional unmanaged indemnity plan.
Mental health benefit design changed dramatically during the 1990s, in
large part due to managed care. Before 1990, most plans provided 80 per-
cent coverage for inpatient care and 50 percent coverage for outpatient
care with annual limits. By the end of the decade, typical plans covered
80 percent of outpatient costs, within annual limits, and more intermedi-
ate services, such as partial hospitalization, intensive day/evening treat-
ment programs, and in-home care. Combined with managed care tech-
niques, such as utilization review, discounted fee arrangements, and pre-
ferred provider networks, employer experiences show that coverage
changes resulted in greater access to outpatient services and cost-effec-
tive alternatives to hospitalization.
The number of people treated for depression increased dramatically over
that same decade, particularly in primary care settings. A study published
in 2002 showed that 6.3 million Americans were treated for depression in
1997, up from 1.7 million in 1987.21 The researchers, using surveys of more
than 30,000 people nationwide, found patients treated for depression were
almost five times more likely to receive an antidepressant in 1997 than
they would have been a decade earlier. In contrast, fewer patients re-
ceived psychotherapy—60 percent in 1997, down from 71 percent in 1987.
However, by 1997 more patients received a combination of medication
and psychotherapy.
Researchers Mark Olfson and colleagues cited several factors contribut-
ing to the increase in people receiving depression treatment: the intro-
duction and marketing of new antidepressants with fewer adverse af-
fects, aggressive public health efforts to increase depression awareness,
and more accepting public attitudes about pharmacological treatments.
In addition, they noted that increased penetration of managed care and
managed behavioral health care may have resulted in incentives for briefer
treatments and more care delivered in primary care settings.
The authors concluded, “treatment became characterized by greater in-
volvement of physicians, greater use of psychotropic medications, and
expanding availability of third-party payment, but fewer outpatient visits
and less use of psychotherapy.” They noted study limitations inherent
to survey research and cited the need to better understand the effects
that treating a greater number of people for depression would have on
population health and patient outcomes.
Health plan and prescription drug benefit manager (PBM) data on anti-
depressant use also reflected increases in the number of people treated
for depression. Antidepressants are among the most highly utilized pre-




1990s, in large part
due to managed care.
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classes in total dollar growth over the last several years typically included
cholesterol reducers, anti-ulcerants, antihistamines, antihypertensives, and
antidepressants.22
The rapid rise in antidepressant expenditures has caught the attention
of large employers sponsoring health benefits. Comparing the patterns
of antidepressant use to depression treatment guidelines leaves many
plan sponsors wondering whether beneficiaries are receiving appropri-
ate care. Typical PBM and health plan data show that most SSRI drug
cost is for single prescriptions, 60 percent of antidepressants are pre-
scribed by primary care physicians, the average number of days of use
is 45, and there is little evidence of follow-up or continuing care.23
Antidepressant-type medications have other uses, such as treatment of
anxiety disorders and bulimia. But it is nearly impossible to know if anti-
depressants are prescribed appropriately because diagnosis codes are not
included with prescriptions. Experts contend it is altogether possible that
overuse of antidepressants coexists with undertreatment of depression.24
DEPRESSION AND PRIMARY CARE
More people receiving treatment for depression can be seen as positive
news. However, there are many unanswered questions about treatment
quality. Numerous studies over many years document poor recognition
and treatment of depression in primary care. Even though it is a common
condition with clear diagnostic criteria, research suggests that depres-
sion is missed in somewhere between one-third and one-half of patients
in primary care.25 Even when depression is recognized, research shows it
is often treated inappropriately.
In 1986, the National Institute of Mental Health launched the Depression
Awareness, Recognition, and Treatment (D/ART) Program, the first fed-
erally funded public and professional education campaign to address a
specific mental illness. The purpose of the professional education portion
of the program was to educate medical and mental health providers about
depression and train them in diagnosis and treatment.26
A major contribution of the D/ART Program was to spotlight several ob-
stacles to improving depression recognition and treatment in primary care.
Provider knowledge about diagnostic criteria and guidelines for treatment
were certainly problems. But it became clear there were more complex fac-
tors. Stigma associated with mental illness, patient confidentiality, lack of
insurance coverage for ongoing treatments, low physician reimbursement,
poor integration between primary and specialty care, and physician time
pressures in the managed care environment all contributed to patients’
receiving less than optimal treatment, even when physicians were knowl-
edgeable about depression.
Suggesting that quality of care for depression in primary care is an on-
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(NCQA) State of Health Care Quality report found that average scores for
antidepressant medication management measures have declined since
1999. The three measures, tracked annually, are based on the federal
Agency for Healthcare Research and Quality guidelines for depression
treatment in primary care.27 Results indicated that even top-performing
plans were having difficulty documenting treatment consistent with the
guidelines in more than half of patients diagnosed with depression.28
Blue Cross Blue Shield of Michigan (BCBSM) has embarked on a major
campaign to educate patients and primary care physicians on recogni-
tion and treatment of depression in primary care as a result of a study
they did to determine “how often depression is treated in a population
with access to a relatively rich benefit, where and how these patients re-
ceive treatment, and how closely this treatment meets nationally recog-
nized treatment guidelines.”29 Professional, pharmacy, and facility claims
for the year beginning October 1998 were used to analyze treatment of
new episodes of depression.
The analysis showed a primary care physician was the first provider
seen in 35 percent of cases. Thirty-two percent of treatment episodes
began with a visit to an outpatient clinic staffed by nonphysician men-
tal health specialists and psychiatrists, 28 percent began with a visit to a
psychiatrist, and 7 percent started with a visit to a nonphysician mental
health provider.
Of more than 2,000 episodes of care studied, 56 percent were treated with
antidepressant medication. However, only 18 percent of medication epi-
sodes met duration and dosage criteria and only 20 percent of patients
had three or more visits within the initiation period. BCBSM found that
three or more follow-up visits after a depression diagnosis was a key fac-
tor in treatment adequacy.
New Primary Care Treatment Models
Several initiatives around the country, many sponsored by major foun-
dations, are testing the effectiveness of new models for depression treat-
ment in primary care. Many of the efforts address the need for structural
changes in both health service delivery and financial incentives for phy-
sicians to provide high-quality care.
For example, the MacArthur Foundation is sponsoring a variety of projects
to examine “how—and how well—primary care physicians diagnose and
treat depression in their patients, and how they can improve their effec-
tiveness in both areas.”30 Established in 1997, the program reports in-
sights from the initiative about how physicians manage depression:
Most physicians agree that recognizing depression is part of their re-
sponsibility. However, they differ across specialties in their view of
their responsibility for treatment and in their confidence in their ability
to treat depression effectively. Physicians are pragmatic. They choose
9
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how to manage patients with depression according to the severity of
dysfunction, rather than traditional diagnostic criteria.31
In another prominent effort, the Robert Wood Johnson Foundation in
2002 launched a five-year program, “Depression in Primary Care: Link-
ing Clinical and System Strategies,” to increase the use of effective treat-
ment models for depression in primary care. A major theme of the pro-
gram is recognition that “multilevel clinical and economic/system strat-
egies are needed to overcome barriers among target groups and imple-
ment chronic illness care models for depression in primary care.”32
A collaborative care model or team approach to depression treatment,
pioneered by clinicians at the University of Washington in Seattle, is fea-
tured in several demonstrations throughout the country. For example,
Project IMPACT, a multicenter initiative coordinated at UCLA and funded
by the John A. Hartford Foundation and the California HealthCare Foun-
dation, uses a disease management model and team approach to manag-
ing late life depression.33 The IMPACT model addresses a number of bar-
riers to effective treatment in primary care, such as the limited ability of
primary care providers to follow-up with patients prescribed antidepres-
sants and/or referred for psychotherapy.
Project IMPACT features a depression clinical specialist (DCS), who pro-
vides patient follow-up to “assess side effects and symptom relief for
patients taking antidepressants, and is trained to offer a brief (6-8 ses-
sion) form of psychotherapy called Problem-Solving Treatment for pa-
tients who prefer counseling.”34 A psychiatrist and primary care physi-
cian within a collaborative care team support the DCS. Almost 2,000 older
adults in 18 participating clinics were enrolled in the program over the
last two years. Researchers will track patients for two years, assessing
health and economic outcomes, including effects of the treatment model
on diabetes and other conditions commonly coexisting with depression.
A number of health plan initiatives highlighting a variety of models and
tools for depression recognition and treatment in primary care were
documented in a 2001 Healthplan article published by the American As-
sociation of Health Plans.35 Among the initiatives are consultation and
case management models, along with co-location of primary and behav-
ioral health providers, and telephonic and Internet tools for physicians
and patients.
One example is “Taking Charge of Depression,” a program of PacifiCare
Behavioral Health, a subsidiary of PacifiCare Health Systems. The pro-
gram uses specially trained health educators to coach patients in manag-
ing their depression. In addition, primary care physicians are provided
algorithms for depression treatment and easy access to behavioral health
specialists for consultations. A state-of-the-art outcomes tracking and
monitoring system called ALERT (Algorithms for Effective Reporting
and Treatment), notifies physicians about patient progress and alerts
them to problems with treatment.
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Other efforts to provide primary care providers with tools for depres-
sion diagnosis and treatment evolve from the theory that generalists
may have difficulty incorporating disease-specific solutions into their
practice. Tools and strategies are being developed to help primary care
providers use a general line of questioning to uncover potential mental
health problems and then move quickly to more specific diagnostic strat-
egies, if warranted.
DEPRESSION AS A PUBLIC POLICY CONCERN
The costly consequences of unrecognized and poorly treated depres-
sion are clear. From avoidable health care spending and productivity
losses to death by suicide and devastation for families, there are good
reasons to make improved depression recognition and treatment a pub-
lic health policy priority. In the 1996 book, Caring for Depression, Kenneth
Wells and colleagues link public policy to depression care, saying “qual-
ity improvement for the care of depression is necessary to improve the
value of care.”36
Acknowledging the serious and costly consequences of unrecognized and
poorly managed depression, the U.S. Preventive Services Task Force, an
independent and influential panel of experts sponsored by the U.S. De-
partment of Health and Human Services, recommended in May 2002 that
doctors routinely screen all adult patients for depression and have systems
in place to ensure effective treatment and follow-up. The panel recom-
mended that physicians ask their patients at least two questions, “Over the
past two weeks, have you ever felt down, depressed, or hopeless?” and
“Have you felt little interest or pleasure in doing things?” If a patient an-
swers yes to either question, a more thorough screening is recommended.
Although mental health typically takes a back seat to other health care policy
issues, coverage for mental health services, specifically parity coverage with
medical care, has been a visible issue since debate over the health plan
proposed by the Clinton administration and enactment of the Mental Health
Parity Act in 1996. The parity law’s scope was more limited than desired
by mental health advocates, requiring parity in annual and lifetime dollar
limits but not prohibiting other controls such as day and visit limits. De-
spite the continued limits, the debate highlighted the relatively low cost of
mental health care and the indirect benefits of better access to services,
leading some experts to believe the law’s enactment signaled the begin-
ning of an end to discrimination in mental health coverage.
With the 1996 law scheduled to sunset September 30, 2001, Congress
was engaged in negotiating a new, expanded law when the September
11 terrorist attacks abruptly stopped action on legislation. President Bush
renewed the push for new parity legislation in early 2002, perhaps in
response to heightened public awareness about the mental health ef-
fects of terrorism. Any action, however, will not occur until next year.
“Quality improvement
for the care of depres-
sion is necessary to im-
prove the value of care.”
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In January 2001, the Federal Employee Health Benefit Plan, the largest
employer-sponsored health benefits plan of its kind, began implement-
ing parity for mental health and substance abuse benefits. President
Clinton directed the Office of Personnel Management to incorporate the
benefit in 1999 after several studies demonstrated parity could be achieved
at a manageable cost when provided in a managed care setting.37 A thor-
ough evaluation of the program is underway and results will be avail-
able in late 2003.
With the focus on parity, there has been less attention to other policies that
could improve access to mental health care and create incentives for qual-
ity treatment. One obvious target is the growing number of uninsured and
their lack of access to care. Another is the need for culturally and linguisti-
cally competent primary care and mental health professionals.
One area receiving strong attention is Medicare coverage for outpatient
prescription drugs. Currently, almost three-quarters of Medicare benefi-
ciaries have some outpatient drug benefits. But coverage from the two
leading sources, employer retiree plans and Medicare+Choice plans, is
eroding as a result of cost pressures.
Having prescription drug coverage influences whether Medicare benefi-
ciaries fill their prescriptions and take their medications as directed. As
prescription drugs are an integral part of depression treatment, it makes
sense to expect that Medicare drug coverage would enhance access to
treatment for many seniors. In addition, it is possible that quality of life
and health outcomes would improve for older adults if recognition and
management of depression were improved. Although there is strong bi-
partisan support for the addition of a prescription drug benefit to mod-
ernize Medicare, affordability of new coverage and partisan differences
over how to structure the benefit have hampered the legislation’s progress.
Policy areas that have received little attention are physician reimburse-
ment and incentives for quality treatment. Wells and colleagues discuss
two possible policy avenues for improving depression treatment. The
first is the establishment of standard quality-of-care measures in order
to identify high-quality providers; the second is a reimbursement scheme
that rewards those providers.38 New reimbursement schemes could also
be used to encourage collaborative care models and other team ap-
proaches to depression treatment. The new treatment models may re-
quire increased spending. However, some current spending can be re-
distributed to reward quality, and improved treatment efficiency and
cost avoidance might result in savings.
A scenario along the lines of that described by Wells is evolving in the
area of diabetes care. The American Diabetes Association (ADA)/NCQA
Diabetes Provider Recognition Program is a voluntary program for phy-
sicians and physician groups who provide care for people with diabetes.
Under the program, developed by the ADA, NCQA, Centers for Medi-
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College of Physicians, FACCT (Foundation for Accountability), and the
Veterans Administration, physicians can receive recognition for provid-
ing quality diabetes care based on a set of key measures.39 Several large
health care purchasers are developing reimbursement schedules that
link provider payment to this care quality designation.
In an environment of rising health care costs, it may be difficult to advo-
cate for policies that would increase direct health care spending on de-
pression treatment. On the other hand, there is a strong case for making
a modest spending increase to avoid the significant health care expendi-
tures related to untreated depression, not to mention the huge produc-
tivity and social costs. Approaches that address the complex nature of
the problem, including improving provider knowledge about depres-
sion, increasing mental health coverage, encouraging treatment within
a chronic illness model, and reducing inefficient and poorly managed
care, may stand the best chance of improving access to treatment at an
affordable cost.
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